vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and DONEGAL GROUP INC (DGICA). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $236.0M, roughly 1.1× DONEGAL GROUP INC). DONEGAL GROUP INC runs the higher net margin — 4.9% vs 1.4%, a 3.5% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.7% vs -3.7%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (5.3% CAGR vs -2.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Donegal Group Inc. is a regional US insurance holding company offering personal and commercial property and casualty insurance products. It serves Mid-Atlantic, Midwest, and Southern US customers, delivering tailored coverage for individuals, families, and small to medium businesses.
ACAD vs DGICA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $236.0M |
| Net Profit | $3.6M | $11.5M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | — |
| Net Margin | 1.4% | 4.9% |
| Revenue YoY | 9.7% | -3.7% |
| Net Profit YoY | — | -54.3% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $236.0M | ||
| Q4 25 | $284.0M | $239.8M | ||
| Q3 25 | $278.6M | $245.9M | ||
| Q2 25 | $264.6M | $247.1M | ||
| Q1 25 | $244.3M | $245.2M | ||
| Q4 24 | $259.6M | $250.0M | ||
| Q3 24 | $250.4M | $251.7M | ||
| Q2 24 | $242.0M | $246.8M |
| Q1 26 | $3.6M | $11.5M | ||
| Q4 25 | $273.6M | $17.2M | ||
| Q3 25 | $71.8M | $20.1M | ||
| Q2 25 | $26.7M | $16.9M | ||
| Q1 25 | $19.0M | $25.2M | ||
| Q4 24 | $143.7M | $24.0M | ||
| Q3 24 | $32.8M | $16.8M | ||
| Q2 24 | $33.4M | $4.2M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | 8.7% | ||
| Q3 25 | 12.8% | 10.2% | ||
| Q2 25 | 12.2% | 8.3% | ||
| Q1 25 | 7.9% | 12.7% | ||
| Q4 24 | 59.1% | 11.9% | ||
| Q3 24 | 12.6% | 8.1% | ||
| Q2 24 | 12.6% | 2.0% |
| Q1 26 | 1.4% | 4.9% | ||
| Q4 25 | 96.3% | 7.2% | ||
| Q3 25 | 25.8% | 8.2% | ||
| Q2 25 | 10.1% | 6.8% | ||
| Q1 25 | 7.8% | 10.3% | ||
| Q4 24 | 55.4% | 9.6% | ||
| Q3 24 | 13.1% | 6.7% | ||
| Q2 24 | 13.8% | 1.7% |
| Q1 26 | $0.02 | — | ||
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $649.1M |
| Total Assets | $1.6B | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — |
| Q1 26 | — | $649.1M | ||
| Q4 25 | $1.2B | $640.4M | ||
| Q3 25 | $917.3M | $627.4M | ||
| Q2 25 | $822.4M | $605.7M | ||
| Q1 25 | $765.2M | $584.7M | ||
| Q4 24 | $732.8M | $545.8M | ||
| Q3 24 | $577.2M | $513.4M | ||
| Q2 24 | $516.7M | $484.1M |
| Q1 26 | $1.6B | $2.4B | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.2B | $2.4B | ||
| Q1 25 | $1.1B | $2.4B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $976.9M | $2.3B | ||
| Q2 24 | $914.1M | $2.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
